TGTX TG Therapeutics, Inc.

11.90
+0.05  (0%)
Previous Close 11.85
Open 11.85
Price To book 7.23
Market Cap 733.71M
Shares 61,656,000
Volume 732,631
Short Ratio 1.95
Av. Daily Volume 2,567,740

SEC filingsSee all SEC filings

  1. S-3 - Registration statement under Securities Act of 1933 17874392
  2. 8-K - Current report 17866670
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830474
  4. 8-K - Current report 17816089
  5. 8-K - Current report 17801161

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated October 2016.
TGR-1202
Relapsed or refractory lymphoma - cancer
Phase 2 preliminary results presented at American Academy of Neurology (AAN) annual meeting April 28, 2017.
TG-1101
Multiple Sclerosis
Phase 2b enrollment commenced June 2016. First interim analysis due mid-2017.
TG-1101 and TGR-1202 - UNITY-DLBCL study
Diffuse large B-cell lymphoma (DLBCL) cancer
Phase 3 trial met primary endpoint - March 6, 2017, meeting with FDA in 2H 2017. Oral presentation at ASCO June 3, 2017. Abstract 7504.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 enrollment to be completed end of 2017.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)

Latest News

  1. 5 Stocks Setting Up for Big Breakouts
  2. TG Therapeutics Stock Climbs After Successfully Completed Analysis in UNITY-CLL
  3. TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial
  4. TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : May 22, 2017
  5. TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
  6. TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 22nd European Hematology Association Annual Congress
  7. TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
  8. ETFs with exposure to TG Therapeutics, Inc. : May 15, 2017
  9. TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  10. TG Therapeutics, Inc. – Value Analysis (NASDAQ:TGTX) : May 11, 2017
  11. 3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month
  12. TG Therapeutics reports 1Q loss
  13. TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
  14. TG Therapeutics, Inc. to Host Conference Call on First Quarter 2017 Financial Results and Business Update
  15. 3 Best Biotech Stocks During Trump's First 100 Days
  16. TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting
  17. ETFs with exposure to TG Therapeutics, Inc. : April 26, 2017
  18. Harry Boxer’s two infrastructure stocks to watch
  19. Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics